Differential antianginal responsiveness to acebutolol

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary insufficiency and angina represent significant cardiovascular challenges.
• Cardioselective beta-blockers are used to manage these conditions.

Purpose of the Study:

• To evaluate the efficacy of acebutolol, a new cardioselective beta-blocker, in patients with coronary insufficiency and angina.
• To assess the impact of different acebutolol dosages on exercise performance and anginal symptoms.

Main Methods:

• A double-blind, randomized study involving six males with documented coronary insufficiency.
• Patients underwent graded treadmill exercise tests after ingesting 0, 200, or 400 mg of acebutolol.
• Performance was measured by time to angina/ECG changes, peak heart rate, peak double product, and peak oxygen consumption.

Main Results:

• All measured performance criteria improved with both 200 mg and 400 mg doses of acebutolol, with greater improvement at the higher dose.
• A significant interaction between acebutolol dose and patient response category was observed.
• Patient responsiveness was correlated with placebo performance and other individual factors.

Conclusions:

• Acebutolol demonstrated significant beneficial effects in responders across all evaluated criteria.
• Patients were categorized into distinct responder and non-responder groups.
• Individual factors, including baseline performance, influenced patient sensitivity to acebutolol.